Eloxx Pharmaceuticals(ELOX)

Focus: Eloxx Pharmaceuticals is a public-stage biotech company focused on developing therapies for rare genetic diseases, particularly those affecting the nervous system. The company operates from Arlington, MA with a pipeline concentrated on a single lead asset (ELX-02) across multiple indications.

Rare Diseases Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Eloxx Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Eloxx Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Early-stage

9 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$0K

Pipeline & Clinical Trials

ELX-02

Genetic Disease

PHASE_1

Clinical Trials (1)

NCT03309605Phase 1 Study of ELX-02 in Healthy Adult Subjects

Phase 1

Help build intelligence for Eloxx Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused pipeline with ELX-02 advancing across multiple rare disease indications (cystic fibrosis, Alport syndrome) suggests meaningful clinical validation potential
Public company status provides liquidity and potential equity upside for employees versus private-stage risk
Specialization in rare genetic diseases offers deep scientific focus and potential for meaningful patient impact in underserved populations

Watch Out For

Severe cash depletion: cash position collapsed from $42M (FY2022) to $1M (FY2025) while R&D spend dropped 61%, signaling critical liquidity concerns
Zero active job postings and no disclosed headcount suggest company may be in contraction mode or hibernation
No marketed products, no revenue generation, and negative net income of -$17M (FY2025) indicate pre-commercialization stage with survival risk
All pipeline programs remain in Phase 1-2 with no Phase 3 programs, meaning no near-term regulatory catalysts or revenue visibility

Generated by Claude from Eloxx Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Placebo

Genetic Disease

PHASE_1

Clinical Trials (1)

NCT03292302Phase 1 Study of ELX-02 in Healthy Adults

Phase 1

ELX-02

Impaired Renal Function

PHASE_1

Clinical Trials (1)

NCT03776539A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02

Phase 1

ELX-02

Genetic Diseases

PHASE_1

Clinical Trials (1)

NCT02807961Safety, Tolerability, Pharmacokinetics of ELX-02 in Healthy Adult Volunteers

Phase 1

ELX-02

Alport Syndrome

PHASE_2

Clinical Trials (1)

NCT05448755A Study of ELX-02 in Patients With Alport Syndrome

Phase 2

ELX-02

Genetic Disease

PHASE_2

Clinical Trials (1)

NCT04069260A Phase 2 Study of ELX-02 in Patients With Nephropathic Cystinosis

Phase 2

ELX-02

Cystic Fibrosis

PHASE_2

Clinical Trials (1)

NCT04135495A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele

Phase 2

ELX-02

Cystic Fibrosis

PHASE_2

Clinical Trials (1)

NCT04126473A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele

Phase 2

Exaluren

Alport Syndrome, X-Linked

Phase 2

Clinical Trials (1)

NCT07523581EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 9 clinical trials

Top TAs: Rare Diseases, Nephrology

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Rare Diseases

2 pipeline

Nephrology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

R&D Spend

$9M62%

Net Income

-$17M

Cash

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles